Title : Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Pub. Date : 2016 Mar

PMID : 26908832






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. Tolvaptan arginine vasopressin receptor 2 Homo sapiens